Tower View Investment Management & Research LLC grew its position in shares of Becton Dickinson and Co (NYSE:BDX) by 55.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,128 shares of the medical instruments supplier’s stock after purchasing an additional 2,890 shares during the quarter. Becton Dickinson and comprises approximately 1.9% of Tower View Investment Management & Research LLC’s investment portfolio, making the stock its 27th largest position. Tower View Investment Management & Research LLC’s holdings in Becton Dickinson and were worth $1,831,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in BDX. Fundsmith Equity Fund L.P. purchased a new position in Becton Dickinson and during the 2nd quarter valued at about $894,775,000. Russell Investments Group Ltd. grew its holdings in Becton Dickinson and by 9.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 871,363 shares of the medical instruments supplier’s stock valued at $226,999,000 after buying an additional 76,560 shares in the last quarter. Spinnaker Trust grew its holdings in Becton Dickinson and by 46.3% during the 3rd quarter. Spinnaker Trust now owns 14,922 shares of the medical instruments supplier’s stock valued at $3,894,000 after buying an additional 4,725 shares in the last quarter. Kiwi Wealth Investments Limited Partnership purchased a new position in Becton Dickinson and during the 2nd quarter valued at about $9,161,000. Finally, FMR LLC grew its holdings in Becton Dickinson and by 7.6% during the 2nd quarter. FMR LLC now owns 16,067,452 shares of the medical instruments supplier’s stock valued at $3,849,118,000 after buying an additional 1,129,688 shares in the last quarter. Hedge funds and other institutional investors own 83.77% of the company’s stock.
A number of research firms have weighed in on BDX. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 target price for the company in a report on Tuesday. Piper Jaffray Companies cut their price objective on Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a report on Tuesday, November 6th. Barclays assumed coverage on Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price objective for the company. Morgan Stanley cut their price objective on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating for the company in a report on Wednesday, January 2nd. Finally, Citigroup cut their price objective on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating for the company in a report on Wednesday, January 2nd. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $251.85.
In related news, Director Timothy M. Ring sold 42,000 shares of Becton Dickinson and stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the sale, the director now owns 93,688 shares of the company’s stock, valued at approximately $22,210,614.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Charles R. Bodner sold 2,080 shares of Becton Dickinson and stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $245.83, for a total value of $511,326.40. Following the sale, the senior vice president now directly owns 4,497 shares in the company, valued at approximately $1,105,497.51. The disclosure for this sale can be found here. Insiders sold 81,795 shares of company stock worth $19,571,318 in the last ninety days. Corporate insiders own 0.12% of the company’s stock.
BDX stock traded down $2.30 during midday trading on Friday, hitting $227.15. The stock had a trading volume of 24,036 shares, compared to its average volume of 1,235,191. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $265.87. The stock has a market cap of $61.02 billion, a price-to-earnings ratio of 20.63, a PEG ratio of 1.63 and a beta of 1.21. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 0.90.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting the consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. The company had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period last year, the firm posted $2.40 earnings per share. Becton Dickinson and’s revenue was up 39.0% compared to the same quarter last year. Equities research analysts expect that Becton Dickinson and Co will post 12.11 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 31st. Stockholders of record on Monday, December 10th were paid a $0.77 dividend. The ex-dividend date was Friday, December 7th. This represents a $3.08 annualized dividend and a dividend yield of 1.36%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: Marijuana Stocks Investing Considerations